Multiple Myeloma

Multiple Myeloma had an important presence at ASH 2015, as evident by the steady number of tweets throughout the weekend. It was a highly positive conference for physicians and patients alike, who were abuzz regarding the better efficacy, improved PFS/OS, and potential for MRD given all of the newly approved agents; Darzalex, Ninlaro, and Empliciti, along with Velcade, were mentioned most frequently. Almost two-thirds of tweets related to Ninlaro were expressly positive, while a small subset of tweets regarding Empliciti were negative. Kyprolis also received coverage for updated results from its ENDEAVOR and CHAMPION-1 trials, the former surrounded by more positive conversation. Despite the enthusiasm, some tweets expressed concerned about the high cost of triplet regimens. MM tweets came from a diverse group and among the top tweeting physicians; almost 50k twitter followers learned something new about Myeloma.



Download this infographic.